Medical House Share Discussion Threads

[3monkey] 16/2/2007 09:25

This is a sleeping giant.Yorkshire Post Thurs gave very optimistic resume.
topping up time before the vultures.

[ariane] 13/2/2007 07:12

Medical House Notification of Shareholding


RNS Number:1442R
Medical House PLC
13 February 2007


For immediate release 13 February 2007

The Medical House plc (the "Company")

Notification of Shareholding

In accordance with Section 198-202 of the UK Companies Act 1985, the Company has
on 12 February 2007 received notification from Aviva plc that Vidacos Nominees
Limited and its subsidiary companies have a notifiable interest in 4,298,998
ordinary shares of The Medical House plc, amounting to 7.15% of the issued share
capital.

For further information please contact:

The Medical House [phone]
Mike Mason Company Secretary

Nomura Code Securities [phone]
Wolf Dornbusch




This information is provided by RNS
The company news service from the London Stock Exchange
END

HOLXLLLFDLBFBBL

[unionhall] 12/2/2007 19:00

Exciting it isn't - you got that right !!

I haven't bought in yet...

Your post reminded me of them...

[mjcrockett] 12/2/2007 18:03

Unionhall, I'm here - but this is not my most exciting share! I guess we should get some interest around the interims, which must be due out soon. Perhaps there will be another contract announcement along with the interims. That could be wishful thinking, but they did say there was a high level of interest in their products.

MJ

[unionhall] 29/1/2007 12:26

Nobody at all following these ?

[waldron] 17/12/2006 11:24

£27m injection for Medical House
Ros Snowdon
Deputy City Editor
INJECTION specialist The Medical House has signed a £27m deal to supply its ASI autosafety injector to a leading global pharmaceutical company.
The Sheffield-based company is unable to say who the partner is or which drug will be used because of commercial sensitivities, but it described the deal as a major milestone for the company.
Medical House chairman Ian Townsend said the agreement is ten times bigger than any of its previous deals.
"This is part of a global trend for big pharmaceutical companies to switch to auto-injectors," he said.
The group's previous signing for the ASI was to supply a disposable system for use in emergency applications.
Analysts believe the size of yesterday's deal means the drug will be used in mainstream therapies rather than for emergency use.
At the moment two billion pre-filled syringes are being used every year worldwide.
The Medical House has a superior auto injector system to its rivals as its device has just six plastic components that are easy to assemble.
"We are ahead of our rivals as our device has so few components. It gives a perfect injection every time, it is simple to use and it is considerably cheaper than our rivals," said Mr Townsend.
Last month The Medical House said it was confident of a much better year following disappointing delays in FDA approval for a major contract.
08 December 2006

[waldron] 17/12/2006 10:50

Medical House(The Medical House wins 5-yr 27 mln stg contract from pharma co for its auto injector


LONDON (AFX) - The Medical House PLC (TMH), the drug delivery & orthopaedic
devices group, said it has signed a five year agreement with an undisclosed
global pharma co for 27 mln stg for its needle-based disposable 'AutoSafety
Injector' system.
In this largest contract in the company's history, TMH will customise its
AutoSafety Injector system for the efficient delivery of a currently-undisclosed
drug of its partner.
The company said subject to TMH meeting the partner's customisation
requirements, it is anticipated that commercial product supply will commence in
2008. TMH would receive compensation, in the event that the combination of the
ASI and the customer's drug were not launched.
TMH's ASI auto-injector technology incorporates a pre-filled syringe fitted
with a needle and allows injections to be easily and safely undertaken by
patients themselves or by other non-clinicians such as family members and
colleagues.



[e-mail]
smi/slm

[waldron] 17/12/2006 10:49

Parent thread

[whitebicycle] 08/12/2006 08:48

Only the person who started the thread can put the chart on the header. This sort of deal is what I've been waiting for for years, its been double what it now a few years back.

[benson] 08/12/2006 07:28

Can the chart be put on the header please?

[mjcrockett] 08/12/2006 07:25

Medical House tipped in the Independent today:-

Medical House

Our view: Worth a punt

Share price: 38p (+7.5p).

Medical House unveiled the biggest licensing deal to date for its AutoSafety syringe yesterday. The company could not say who its partner is, but indicated that it was a global pharmaceutical player. More importantly, the deal is worth £27m to Medical House over the next five years and follows a similar tie-up earlier this year with Swiss group Serono.

The AutoSafety syringe is designed to make it easy for patients to administer treatments to themselves and is perfect for those who take regular doses via an injection. Because the needle is hidden from view at all times, patients tend to prefer it over traditional alternatives.

The deal is certainly significant for the company when one considers that even after yesterday's share price jump the whole enterprise is valued at just £22m. With momentum building, its stock is worth a punt.


Perhaps we could see a further rise today.

MJ

[mjcrockett] 07/12/2006 11:42

I agree with you Skyship the stock is way too cheap. The contract announced today is huge for a company with a market cap of only £24m (after today's rise).

The 'leading global pharmaceutical partner' must have a lot of confidence in the technology to sign up to such a deal. There could well be more similar contracts to come.

TMH's turnover last year was £5.6m. This deal projects £27m over 5 years i.e. averaging around the level of the current turnover....AND two thirds of this is in 'technology access fees'.

Huge potential!

MJ

[skyship] 07/12/2006 07:55

Surely this stock has been too cheap too long...path looks clear to 45p.

[whitebicycle] 31/1/2006 11:01

I think these have taken a knock because of Pfizer getting inhaled insulin approved. It hasn't done Bespak (BPK) any harm.

[gerrystewart] 23/1/2006 17:57

Taylora,

Only a guesss, but based on past precedent it isn't beyond the MMs on this stock to drop the price when they are short of stock. Certainly, for the past few weeks, there has been in the region of 60k net 'buys' (not a lot in monetary terms but not inconsiderable given how tightly this stock is held). Indeed, until late last week, it was almost impossible to buy even the NMS (2k) on-lime whereas you could have sold 15-20k and the spread was very small (effectively 0.5p). That suggested they were short of stock. Nothing obvious has happened to turn that around so they might be doing the same again. After all, the first few trades were all MM deals. This was a tactic they used to some effect just after the '05 interims. But, if they are doing it again, it doesn't appear to have netted much by way of 'sells' as far as I can see. They might have to try harder. But, if they do and in the absence of any bad news, I think it offers a great buying opportunity.

[taylora] 23/1/2006 11:31

I notice there is rather a drop in these today. Is anyone else into these and understand what's going on?

[whitebicycle] 01/12/2005 23:19

Anyone been following Bioject they have been asked for more data on injecting Fuzeon which is the drug that ultimatley finished off NMT and their needlestick syringe.

[waldron] 05/10/2005 07:17

Preliminary Results

RNS Number:2102S
Medical House PLC
05 October 2005


For Immediate Release 5 October 2005


The Medical House PLC

Preliminary results for the year ended 30 June 2005

The Medical House PLC ("TMH"), (AIM: MLH) the orthopaedic devices and drug
delivery company, announces its preliminary results for the year ended 30 June
2005.

* Orthopaedic Instruments
- Profit up 75% at #1.24m (2004 : #0.7m)
- Sales up 57% at #8.6m (2004 : #5.47m)
- Strong growth throughout year
- Innovation in design and manufacture - key strengths
- Delay in FDA approval for key customer dampens immediate prospects

* Drug Delivery Systems
- Loss down to #363,000 (2004 : #411,000)
- Sales up 260% at #440,000 (2004 : #122,000)
- Deals with three pharma companies to drive sales in calendar year 2006
- Needle-free and automated needle products - well-received advanced
technology

* Financial Performance
- Group turnover #9.05m (2004 : #5.59m)
- Group operating profit (loss) #0.13m (2004 : #(2.18)m)

* Prospects
- Profit expected in 2006/7
- Short term trading held back by delay to FDA approval


Ian Townsend, Chairman, The Medical House, said:

"It is a pity that the edge has been taken off such a successful year for both
our divisions. The company has come a long way in the past 12 months, although
unfortunately the delay to FDA approval for one of our key customers has
deferred the financial rewards of some of our endeavours. However with
agreements in place for the Drug Delivery division progressing to plan and with
growth in the Orthopaedic division in line with industry projections, 2006/7
should show a useful profit."



For further information:
The Medical House PLC tel: [phone]
Ian Townsend, Chairman www.themedicalhouse.com

Buchanan Communications tel: [phone]
Tim Anderson / Rebecca Skye Dietrich /Lisa Baderoon


Chairman's Statement

The year to 30 June 2005 has been one of yet further progress. Our Orthopaedic
division reported a record year, achieving its highest-ever sales and operating
profits, with our Drug Delivery division making considerable strides forward in
what is a significant and challenging global market.


Eurocut Ltd
Orthopaedic Division 2005 Profit #1.24m (2004: #0.7m)

Eurocut's improved first half sales continued in the second half, resulting in a
record year for both revenues and operating profits. The majority of growth came
from sales to one major customer for a new system which has been very well
received in their market. Unfortunately, as we announced in August, approval for
this product by the US regulator (FDA) has been delayed which resulted in a
dip in orders. The effects of this will be felt in the first half of 2005/6, but
this should not be allowed to detract from the excellent performance in 2004/5.
Even if we were much larger with a wider range of customers placing large
volumes of business with us, such a situation would still have a significant
detrimental effect on sales and earnings as it inevitably takes time to replace
work, and re-build the order book. Further the work which is more readily
available tends to be at lower margins and may not be of the optimum mix to
fully utilise all of our available production facilities.

In order to mitigate the effects of any recurrence of such a situation, Eurocut
is seeking to enter into more Vendor Managed Inventory (VMI) partnerships,
enabling instruments to be made for stock, based upon customers' forward
commitments, which provides the combined advantages of rapid product
availability and short lead times for customers, as well as improved
manufacturing efficiencies at Eurocut. We already supply DePuy (a subsidiary of
Johnson and Johnson) with their new image-guided knee system instrumentation on
such a VMI arrangement and we are actively working to expand this approach with
other key customers in the coming year. Another feature of VMI agreements is
that they do have a short-term impact on working capital as instruments are
initially made for stock and invoiced to the customer as they are called off.

We have a tremendous asset in our capability to design and manufacture
innovative solutions for the orthopaedic market, but in the past this has always
been on a subcontract basis for our customers. By developing concepts and
technologies in which the intellectual property is owned by Eurocut, we not only
give ourselves the opportunity to create new revenue streams but we also greatly
add to the value of our business.

I am pleased to reveal that during the past year we developed a colour coding
process for all sized instruments, assisting surgeons by simplifying the
selection of the appropriate instrument during a surgical procedure. This
process enables the embedding of coloured polymers within these instruments to
indicate instrument size, with the coloured polymer remaining intact throughout
repeated cleaning and sterilisation of the instrument. Such colour coding is
already attracting considerable interest from our customers and we are
progressing regulatory approval with a major customer. Although sales are
unlikely to be generated from this colour coding system before 2006/7, this will
meet a considerable market need and represents a significant opportunity. This
is a good example of an area in which Eurocut can generate a great deal of
future sales, as orthopaedic companies continually seek innovative ideas and
solutions to differentiate themselves from their competitors.

The opportunity for growth at Eurocut is as good as ever and with recent
investment in capital equipment we are confident of increasing sales
significantly, without the need for any major additional capital expenditure.
The company currently has a day shift and smaller night shift, which represents
considerable scope for revenue growth by improving machine utilisation and
increasing manufacturing capacity.

The current order book is below the corresponding level of last year, primarily
because of the delay in FDA approval on one of our major production items as
announced in August. However, this situation will reverse in due course as this
particular customer places more orders to replenish its stocks and as additional
new business is won from elsewhere. The likelihood is that the year just started
will now be a challenging period rather than one of continued growth which we
would have experienced had this customer's US regulatory approval not been
delayed. Finally, I would like to thank our Eurocut employees for their hard
work during what still has been an excellent year, despite the recent
disappointment.



Medical House Products Ltd
Drug Delivery Division 2005 Loss #363,000 (2004: Loss #411,000)

Our Drug Delivery division made some major steps forward in the past year which
will result in significant sales in 2006 and beyond. Revenues grew strongly to
#440,000 (2004: #122,000) as a result of improved device sales coupled with
development fees received from our customers and licensees. Although this growth
is encouraging, our revenues are still relatively small in relation to the
overall global drug delivery market in which we are operating. We fully
anticipate that sales will move ahead strongly during the calendar year 2006 as
we commence supplies of devices and consumables to three pharmaceutical
companies with whom we have signed development, license and supply agreements.
These include Serono and BioPartners, both of whom will be supplied with
needle-free devices for injection of their respective human growth hormone (hGH)
products. Additionally, in 2006 we will commence sales to our as-yet undisclosed
pharmaceutical company partner for the ASI disposable autoinjector.

At this point it is perhaps worth expanding on our future strategy for further
growth, in order that shareholders can better appreciate the potential which
exists in the global drug delivery market for this division.

Firstly, there is the needle-free injector market which although attractive, is
undoubtedly a difficult market in which to achieve rapid growth since it is
represents a significant change to traditional, needle-based injections. It is
also worth noting that only a relatively small number of injectable drugs are
currently regarded suitable for needle-free injections, with the major
candidates being insulin, human growth hormone and local anaesthetics.

Despite the fact that fewer patients (typically children) receive human growth
hormone than insulin, the hGH market is more developed than the market for
needle-free injection of insulin. This relates to the fact that pharmaceutical
companies such as Serono are prepared to spend more time and resource supporting
needle-free injection of their hGH, which has a higher cost than insulin. The
overall market for insulin is much bigger, but is dominated by companies which
promote needle-based pen injectors on the basis of user-convenience, although
needle-free systems have a number of major advantages in avoiding needlestick
injury risks and need for sharps disposals, as well as helping patients to
overcome anxieties associated with needles. Nevertheless we continue to pursue
sales in the insulin market through a number of distributors, which are in the
process of obtaining local regulatory approvals. Our own experience in the UK,
however, indicates that even when the product is provided free-of-charge, a
significant cultural shift is needed to generate a major movement away from
needle-based systems.

Consequently, although we will be assisting our distributors in every way we can
it would be imprudent to expect too much too soon from them. The new SQ-PEN
needle-free insulin injector has passed all relevant European regulatory
approvals (including NHS Drug Tariff approval) and will be launched in the UK in
December 2005, replacing the mhi-500 which will be withdrawn at the end of this
calendar year. It is worth emphasising that the credibility engendered by these
insulin delivery devices has probably surpassed their sales value and that this
credibility has brought several major pharmaceutical companies to our Sheffield
premises to further investigate our technologies and capabilities. From such
discussions we have signed agreements for both needle-free and the ASI
needle-based autoinjector delivery systems.

Indeed, it is the ASI autoinjector, incorporating drugs packaged in prefilled
syringes, which is undoubtedly attracting most current interest from potential
licensees and partners from the pharmaceutical and biotechnology industries. The
particular attractions of the ASI relate to:

* A very simple, completely automated injection process which involves only
two user steps.

* The needle is hidden from the patient at all times

* Compatibility with all standard prefilled syringes, enabling efficient,
cost-effective commercialisation on behalf of pharmaceutical companies

* Consistency of injection, even by those (such as patients themselves) who
possess no specific clinical expertise

* A small number of device components, creating an inherently reliable and
economic system.

Each year, more than one billion doses of drugs are packaged in prefilled
syringes; in extremely competitive pharmaceutical markets, where companies are
looking to create and maintain marketing advantages, the ASI autoinjector
represents a very attractive proposition.

It has always been my view that large pharmaceutical companies with blockbuster
drugs (i.e. with sales in excess of $1bn) will always be cautious about
partnering these drugs, and their high sales volumes, with companies which may
have limited track records. This is one reason why the signing of license and
supply deals with Serono and other pharmaceutical companies, along with NHS Drug
Tariff approval for our mhi-500 injector, have been so important for the
development and future prospects of this division. I now believe we have a
demonstrable track record of achievement and delivery to support our products
and I am confident that further deals will follow for the ASI and other variants
of this particular technology. Additionally, it is worth pointing out that the
current deal for the ASI, and much of the interest from elsewhere is for a
disposable device but that we also have plans for a re-useable version which may
have appeal for injection of insulin and other drugs.

In summary, our Drug Delivery division continues to make excellent progress and
I anticipate reporting further deals for our devices in the current year.

Dividend

Our policy of developing and bringing new products to market remains unchanged
and the Board does not therefore recommend a dividend in the year to 30 June
2005

Colleagues

The progress we continue to make is only possible due to the key skills and
dedication of our staff who continually demonstrate their commitment to the
business. On behalf of the Board I express sincere thanks to them all.

Current Trading and Prospects

As things currently stand, orthopaedic sales are likely to be below those
achieved in the year just ended and consequently despite an improving Drug
Delivery division I would expect the Group's trading performance in the year
just started to be below the level we are currently reporting.

However, with the agreements in place for the Drug Delivery division progressing
to plan, and with growth in the Orthopaedic division in-line with industry
projections, 2006/7 should show a useful profit.


Ian Townsend
5 October 2005

[waldron] 23/9/2005 07:28

Notice of Results

RNS Number:6549R
Medical House PLC
23 September 2005


For Immediate Release 23 September 2005



The Medical House PLC

Notification of Preliminary Results


Medical House PLC ("TMH"), (AIM:MLH) the orthopaedic devices and drug delivery
company, notifies the London Stock Exchange that they will be reporting their
preliminary results for the year ended 30 June, 2005 on Wednesday 5 October,
2005.



-Ends-





For further information
Buchanan Communications
Rebecca Skye Dietrich 0207 7466 5000



Notes to Editors: About The Medical House (TMH)


Historically the majority of the Group's turnover has come from its orthopaedic
company, Eurocut Limited. It designs and manufactures instruments and systems
used in orthopaedic procedures for many of the world's leading orthopaedic
companies. Eurocut was established in 1988 and now has a reputation as one of
Europe's leading orthopaedic instrument businesses. In January 2004, the company
moved into enlarged premises enabling it to expand sales significantly. This
enables Eurocut to take advantage of a growing orthopaedic market which has an
increasing demand for ever more complex instrumentation to carry out minimally
invasive and image guided procedures.


TMH has progressively been developing needle-free devices which are already
successfully used in the market. TMH's own proprietary next generation device,
the SQ-Pen, its latest spring powered re-usable system, has great potential in
drug delivery worldwide. TMH also has several distribution agreements in place
for the insulin market for its range of reusable needle-free insulin injectors.


TMH announced in November 2002 that it had received approval from the PPA
(Prescription Pricing Authority) for the admission of the mhi-500 device to the
NHS Drug Tariff, to be effective from 1 January 2003. This has enabled the
device and the related consumables to be prescribed on a free-of-charge basis to
the more than 500,000 people with diabetes in the UK who inject insulin daily.
This makes the mhi-500 the first needle-free injection system for liquid
pharmaceuticals to be available on the UK NHS Drug Tariff.


In September 2004 TMH signed an agreement with Serono to develop and supply with
a new needle free system for use with their human growth hormone. The market for
human growth hormone drugs is expected to reach $2.2 billion by 2006 according
to AS Insights.


In February 2005 TMH announced a 10-year agreement which it has signed with
BioPartners GmbH, to supply its GH1 needle-free system for the delivery of
BioPartners' Human Growth Hormone products.


In June 2005, TMH announced that it had signed a binding term sheet with an
undisclosed pharmaceutical company for the license and supply of its ASI
disposable autoinjector system.





This information is provided by RNS
The company news service from the London Stock Exchange
END

NORILFVDAEIFFIE

[grupo guitarlumber] 17/8/2005 06:31

Delays put Medical House in the red
By Stephen Foley
Published: 17 August 2005
The Medical House, a company which develops precision instruments used in hip and knee replacement operations, said regulatory delays for a new product would plunge the company into the red this year.

US regulators are demanding more trials of a new implant from a bigger orthopaedics company which is using the Medical House to supply at least one of the associated surgical instruments. It means supplies of the Medical House's instruments will not be needed in high quantities until the second half of 2006 - a year later than expected.

Shares in the Medical House fell 9 per cent to 67p yesterday, valuing the company at £41.2m.

The commercially sensitive nature of the delay meant the company was unable to name its partner or describe the product that led to the profit warning.

Michael King, analyst at Code Securities, said: "We don't know the product or who the partner is, but we know this is a relatively large product launch. With the regulatory delay, the partner is naturally putting the orders on hold."

The European launch of the product and stockpiling of instruments ahead of the US approval sent sales at the Medical House's orthopaedics division up 58 per cent on last year, which was still disappointing. The group as a whole will show a small loss for the year to 30 June, compared to a £46,000 profit last year.

There will also be a loss in the first half of the new financial year.

[taylora] 13/7/2005 12:27

RNS Number:8044O
Medical House PLC
13 July 2005



For Immediate Release 13 July 2005



The Medical House PLC
Issue of 189,000 shares pursuant exercise of options


Medical House PLC (AIM:MLH) the orthopaedic devices and drug delivery company,
today announces that it has issued 189,000 new ordinary shares of 1p each ("new
Ordinary Shares") pursuant to the exercise of options.


The issue of the new Ordinary Shares is subject to the new Ordinary Shares being
admitted to trading on AIM, application for which has been made. Trading in the
new Ordinary Shares, which will rank pari passu in all respects with the
existing ordinary shares, is expected to commence on 15 July 2005.

Could this be the reason?

[taylora] 12/7/2005 15:45

Very quiet bb. Why the rise today?